One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Text Mining of Electronic Health Records Can Accurately Identify and Characterize Patients With Systemic Lupus Erythematosus
Tammo E. Brunekreef, 1 Henny G. Otten, 1 Suzanne C. van den Bosch, 1 Imo E. Hoefer, 1 Jacob M. van Laar, 1 Maarten Limper, 1 and Saskia Haitjemacorresponding author 1
doi : 10.1002/acr2.11211
ACR Open Rheumatol. 2021 Feb; 3(2): 65–71.
Electronic health records (EHR) are increasingly being recognized as a major source of data reusable for medical research and quality monitoring, although patient identification and assessment of symptoms (characterization) remain challenging, especially in complex diseases such as systemic lupus erythematosus (SLE). Current coding systems are unable to assess information recorded in the physician’s free?text notes. This study shows that text mining can be used as a reliable alternative.
Identification of Acute Giant Cell Arteritis in Real?World Data Using Administrative Claims?Based Algorithms
Hemin Lee, 1 Sara K. Tedeschi, 1 Sarah K. Chen, 1 Paul A. Monach, 2 Erin Kim, 1 Jun Liu, 1 Attila Pethoe?Schramm, 3 Vincent Yau, 4 and Seoyoung C. Kimcorresponding author 1
doi : 10.1002/acr2.11218
ACR Open Rheumatol. 2021 Feb; 3(2): 72–78.
The objective of this study was to validate claims?based algorithms for identifying acute giant cell arteritis (GCA) that will help generate real?world evidence on comparative effectiveness research and epidemiologic studies. Among patients identified by the GCA algorithm, we further investigated whether GCA flares could be detected by using claims data.
Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments
Yih Chang Lin, 1 Mohamad A. Kalot, 2 Nedaa M. Husainat, 3 Kevin Byram, 4 Anisha B. Dua, 5 Karen E. James, 6 Jason M. Springer, 4 Marat Turgunbaev, 7 Alexandra Villa?Forte, 8 Andy Abril, 9 Carol Langford, 8 Mehrdad Maz, 10 Sharon A. Chung, 11 and Reem A. Mustafacorresponding author 10 , 12
doi : 10.1002/acr2.11189
ACR Open Rheumatol. 2021 Feb; 3(2): 91–100.
The object of this study was to analyze the benefits and harms of different treatment options and to analyze test accuracy used in the evaluation of patients with primary systemic polyarteritis nodosa (PAN).
Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta?Analysis of Test Accuracy and Benefits and Harms of Common Treatments
Jason M. Springer, 1 Mohamad A. Kalot, 2 Nedaa M. Husainat, 3 Kevin W. Byram, 1 Anisha B. Dua, 4 Karen E. James, 5 Yih Chang Lin, 6 Marat Turgunbaev, 7 Alexandra Villa?Forte, 8 Andy Abril, 9 Carol A. Langford, 8 Mehrdad Maz, 10 Sharon A. Chung, 11 and Reem A. Mustafacorresponding author 10
doi : 10.1002/acr2.11194
ACR Open Rheumatol. 2021 Feb; 3(2): 101–110.
Eosinophilic granulomatosis with polyangiitis (EGPA) is part of a group of vasculitides commonly referred to as antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), in addition to granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal?limited vasculitis. Patients with EGPA characteristically have asthma and marked peripheral eosinophilia with only approximately 30% to 35% of patients being myeloperoxidase (MPO)?ANCA positive, distinguishing it from other forms of AAV (1,2). The aim of this systematic review is to support the development of the American College of Rheumatology/Vasculitis Foundation guideline for the management of EGPA.
A Multianalyte Assay Panel With Cell?Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus
Rosalind Ramsey?Goldman, 1 Roberta Vezza Alexander, 2 John Conklin, 2 Cristina Arriens, 3 Sonali Narain, 4 Elena M. Massarotti, 5 Daniel J. Wallace, 6 Christopher E. Collins, 7 Amit Saxena, 8 Chaim Putterman, 9 Kelley Brady, 2 Kenneth C. Kalunian, 10 and Arthur Weinsteincorresponding author 11
doi : 10.1002/acr2.11219
ACR Open Rheumatol. 2021 Feb; 3(2): 116–123.
To evaluate the usefulness of biomarkers to predict the evolution of patients suspected of systemic lupus erythematosus (SLE), designated as probable SLE (pSLE), into classifiable SLE according to the American College of Rheumatology (ACR) classification criteria.
Clinical Images: Papulonecrotic tuberculid and Poncet disease
Ran Cui, 1 Sheng?Ming Dai, 1 and Zhiyong Chencorresponding author 1
doi : 10.1002/acr2.11224
ACR Open Rheumatol. 2021 Feb; 3(2): 79.
Takayasu Arteritis: a Systematic Review and Meta?Analysis of Test Accuracy and Benefits and Harms of Common Treatments
Anisha B. Dua, 1 Mohamad A. Kalot, 2 Nedaa M. Husainat, 3 Kevin Byram, 4 Jason M. Springer, 4 Karen E. James, 5 Yih Chang Lin, 6 Marat Turgunbaev, 7 Alexandra Villa?Forte, 8 Andy Abril, 9 Carol Langford, 8 Mehrdad Maz, 10 Sharon A. Chung, 11 and Reem A. Mustafacorresponding author 10
doi : 10.1002/acr2.11186
ACR Open Rheumatol. 2021 Feb; 3(2): 80–90.
Takayasu’s arteritis (TAK) is a granulomatous large?vessel vasculitis primarily affecting the aorta and its proximal branches. TAK can be a difficult disease to diagnose and manage given the rarity of the disease as well as current limitations in biomarkers, imperfect imaging modalities, and few randomized controlled trials.
Autoimmune and Chronic Inflammatory Disease Patients with COVID?19
Ryan C. Ungaro,corresponding author 1 Manasi Agrawal, 1 Sarah Park, 1 Robert Hirten, 1 Jean?Frederic Colombel, 1 Kathryn Twyman, 1 Percio S. Gulko, 1 and Eyal Klang 1
doi : 10.1002/acr2.11221
ACR Open Rheumatol. 2021 Feb; 3(2): 111–115.
There are limited data on the impact of coronavirus disease 2019 (COVID?19) on hospitalized patients with autoimmune and chronic inflammatory disease (AICID) compared with patients who do not have AICID. We sought to evaluate whether patients with AICID who have confirmed COVID?19 presenting to the hospital are at higher risk of adverse outcomes compared with those patients without AICID who are infected with COVID?19 and whether immunosuppressive medications impact this risk.
